Literature DB >> 29493063

Cardiovascular autonomic dysfunction in insomnia patients with objective short sleep duration.

Denise C Jarrin1,2, Hans Ivers1,2, Manon Lamy1,2, Ivy Y Chen1,2,3, Allison G Harvey4, Charles M Morin1,2.   

Abstract

Two phenotypes have been proposed: insomnia with objective near-normal sleep duration, related to increased psychological symptoms, and insomnia with objective short sleep duration, associated with cardiometabolic morbidity. Reduced heart rate variability has also been implicated in the pathophysiology of cardiometabolic disease; however, there are little data on whether cardiovascular function differs between patients with objective short sleep duration and near-normal sleep duration. Participants (Mage  = 49.9 ± 11.3 years; 62.8% female) were 180 adults with chronic insomnia (Mduration  = 15.7 ± 13.6). Objective sleep duration was based on total sleep time averaged across two consecutive nights of polysomnography and subjective sleep duration was based on 2-week sleep diaries. The sample was divided into two groups, with sleep duration shorter (polysomnography-total sleep time: n = 46; sleep diary: n = 95) or equal/longer (polysomnography-total sleep time: n = 134; sleep diary: n = 85) than 6 hr. Electrocardiogram data derived from polysomnography were used to obtain heart rate and heart rate variability during stage 2 (N2) and rapid eye movement sleep. Heart rate variability measures included absolute and normalized high-frequency component, an index of parasympathetic activation, and the ratio of low- to high-frequency (LF/HF ratio), an index of sympathovagal balance. After controlling for covariates (e.g., co-morbidity), patients with objective short sleep duration had reduced high-frequency (p < .05) and elevated low-frequency/high-frequency ratio (p = .036) and heart rate (p = .051) compared with patients with near-normal sleep duration. No differences were observed between phenotypes when subjective sleep duration was used. Insomnia patients with objective short sleep duration showed significantly dampened parasympathetic activation and increased sympathovagal imbalance relative to their counterparts with near-normal sleep duration. These findings highlight the importance of treating insomnia, as treatment may reduce the risk of cardiovascular disease.
© 2018 European Sleep Research Society.

Entities:  

Keywords:  Fourier analysis; RR variability; autonomic functioning; cardiovascualr activity; hyperarousal

Mesh:

Year:  2018        PMID: 29493063      PMCID: PMC5992004          DOI: 10.1111/jsr.12663

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  32 in total

1.  Vagal influence on working memory and attention.

Authors:  Anita Lill Hansen; Bjørn Helge Johnsen; Julian F Thayer
Journal:  Int J Psychophysiol       Date:  2003-06       Impact factor: 2.997

2.  Heart rate variability is associated with glycemic status after controlling for components of the metabolic syndrome.

Authors:  Marc N Jarczok; Jian Li; Daniel Mauss; Joachim E Fischer; Julian F Thayer
Journal:  Int J Cardiol       Date:  2012-03-03       Impact factor: 4.164

3.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

4.  Heart rate variability, overnight urinary norepinephrine, and plasma cholesterol in apparently healthy human adults.

Authors:  Julian F Thayer; Joachim E Fischer
Journal:  Int J Cardiol       Date:  2011-06-08       Impact factor: 4.164

5.  Heart rate and heart rate variability in subjectively reported insomnia.

Authors:  Kai Spiegelhalder; Lena Fuchs; Johannes Ladwig; Simon D Kyle; Christoph Nissen; Ulrich Voderholzer; Bernd Feige; Dieter Riemann
Journal:  J Sleep Res       Date:  2011-03       Impact factor: 3.981

Review 6.  Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder.

Authors:  Alexandros N Vgontzas; Julio Fernandez-Mendoza; Duanping Liao; Edward O Bixler
Journal:  Sleep Med Rev       Date:  2013-02-16       Impact factor: 11.609

Review 7.  The role of vagal function in the risk for cardiovascular disease and mortality.

Authors:  Julian F Thayer; Richard D Lane
Journal:  Biol Psychol       Date:  2006-12-19       Impact factor: 3.251

8.  Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort.

Authors:  Julio Fernandez-Mendoza; Alexandros N Vgontzas; Duanping Liao; Michele L Shaffer; Antonio Vela-Bueno; Maria Basta; Edward O Bixler
Journal:  Hypertension       Date:  2012-08-14       Impact factor: 10.190

9.  The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.

Authors:  Charles M Morin; Geneviève Belleville; Lynda Bélanger; Hans Ivers
Journal:  Sleep       Date:  2011-05-01       Impact factor: 5.849

10.  Insomnia with objective short sleep duration is associated with longer duration of insomnia in the Freiburg Insomnia Cohort compared to insomnia with normal sleep duration, but not with hypertension.

Authors:  Anna F Johann; Elisabeth Hertenstein; Simon D Kyle; Chiara Baglioni; Bernd Feige; Christoph Nissen; Alastair J McGinness; Dieter Riemann; Kai Spiegelhalder
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

View more
  18 in total

Review 1.  Sleep Duration and Blood Pressure: Recent Advances and Future Directions.

Authors:  Nour Makarem; Ari Shechter; Mercedes R Carnethon; Janet M Mullington; Martica H Hall; Marwah Abdalla
Journal:  Curr Hypertens Rep       Date:  2019-04-05       Impact factor: 5.369

Review 2.  Sleep disturbances: one of the culprits of obesity-related cardiovascular risk?

Authors:  Giovanna Muscogiuri; Dario Tuccinardi; Vincenzo Nicastro; Luigi Barrea; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

Review 3.  Autonomic regulation during sleep and wakefulness: a review with implications for defining the pathophysiology of neurological disorders.

Authors:  Anne M Fink; Ulf G Bronas; Michael W Calik
Journal:  Clin Auton Res       Date:  2018-08-28       Impact factor: 4.435

4.  Association of insomnia phenotypes based on polysomnography-measured sleep duration with suicidal ideation and attempts.

Authors:  Kevin G Saulnier; Rupsha Singh; Kristina P Lenker; Susan L Calhoun; Fan He; Duanping Liao; Alexandros N Vgontzas; Edward O Bixler; Julio Fernandez-Mendoza
Journal:  Sleep Health       Date:  2022-06-19

5.  Reliability of heart rate variability during stable and disrupted polysomnographic sleep.

Authors:  Emma M Kerkering; Ian M Greenlund; Jeremy A Bigalke; Gianna C L Migliaccio; Carl A Smoot; Jason R Carter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-05-13       Impact factor: 5.125

6.  Insomnia with objective short sleep duration is associated with cognitive impairment: a first look at cardiometabolic contributors to brain health.

Authors:  Julio Fernandez-Mendoza; Fan He; Kristina Puzino; Gregory Amatrudo; Susan Calhoun; Duanping Liao; Alexandros N Vgontzas; Edward Bixler
Journal:  Sleep       Date:  2021-01-21       Impact factor: 5.849

7.  Short Sleep, Insomnia, and Cardiovascular Disease.

Authors:  Caleb G Hsieh; Jennifer L Martin
Journal:  Curr Sleep Med Rep       Date:  2019-11-29

Review 8.  Insomnia and circadian misalignment: an underexplored interaction towards cardiometabolic risk.

Authors:  Barbara Nobre; Isabel Rocha; Charles M Morin; Miguel Meira E Cruz
Journal:  Sleep Sci       Date:  2021 Jan-Mar

9.  Blunted heart rate recovery to spontaneous nocturnal arousals in short-sleeping adults.

Authors:  Jeremy A Bigalke; Ian M Greenlund; Jennifer R Nicevski; Carl A Smoot; Benjamin Oosterhoff; Neha A John-Henderson; Jason R Carter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-07-30       Impact factor: 5.125

10.  Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial.

Authors:  Yohannes W Woldeamanuel; Douglas W Blayney; Booil Jo; Sophie E Fisher; Catherine Benedict; Ingrid Oakley-Girvan; Shelli R Kesler; Oxana Palesh
Journal:  Cancer       Date:  2021-08-06       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.